Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

Duration of Major Molecular Response (MMR)

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
Full Range
Time frame
216 Weeks

What was measured

Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.

Analysis population: MMR responder set included participants who achieved MMR at any time on randomized treatment. FAS comprised of all randomized participants.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Bosutinib

Participants randomized to bosutinib 500mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib74
Bosutinib19

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
AsciminibNANot reportedNANANA: Not estimable due to insufficient events observed
BosutinibNANot reportedNANANA: Not estimable due to insufficient events observed
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA: Not estimable due to insufficient events observed
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      2. comment
        NA: Not estimable due to insufficient events observed
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    2. group Id
      OG001
      value
      19
    units
    Participants
description
Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.
dispersion Type
Full Range
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
  2. description
    Participants randomized to bosutinib 500mg QD
    id
    OG001
    title
    Bosutinib
param Type
MEDIAN
population Description
MMR responder set included participants who achieved MMR at any time on randomized treatment. FAS comprised of all randomized participants.
reporting Status
POSTED
time Frame
216 Weeks
title
Duration of Major Molecular Response (MMR)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice